Difference between revisions of "Trabectedin (Yondelis)"
Jump to navigation
Jump to search
m |
(updated links) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: | + | Class/mechanism: Alkylator, binds to the minor groove of DNA, which distorts the DNA helix and its major groove. This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.<ref name="insert">[https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/YONDELIS-pi.pdf Trabectedin (Yondelis) package insert]</ref><ref>[[Media:Trabectedin.pdf|Trabectedin (Yondelis) package insert (locally hosted backup)]]</ref><ref>[https://www.yondelis.com/ Yondelis manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
| Line 13: | Line 13: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/YONDELIS-pi.pdf Trabectedin (Yondelis) package insert]<ref name="insert"></ref> |
| − | *[https://www.yondelis.com/ | + | *[https://www.yondelis.com/patient Trabectedin (Yondelis) patient drug information from manufacturer]<ref>[https://www.yondelis.com/patient Trabectedin (Yondelis) patient drug information from manufacturer]</ref> |
*[http://chemocare.com/chemotherapy/drug-info/trabectedin.aspx Trabectedin (Yondelis) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/trabectedin.aspx Trabectedin (Yondelis) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/trabectedin.aspx Trabectedin (Yondelis) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/trabectedin.aspx Trabectedin (Yondelis) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 10/23/2015: FDA approved for the treatment of patients with unresectable or metastatic [[liposarcoma]] or [[leiomyosarcoma]] who have received a prior [[Regimen_classes#Anthracycline-based_regimen|anthracycline-containing regimen]]. | + | * 10/23/2015: [https://pubmed.ncbi.nlm.nih.gov/28774898/ FDA approved] for the treatment of patients with unresectable or metastatic [[liposarcoma]] or [[leiomyosarcoma]] who have received a prior [[Regimen_classes#Anthracycline-based_regimen|anthracycline-containing regimen]]. |
==Also known as== | ==Also known as== | ||
| Line 31: | Line 31: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Vesicant]] | [[Category:Vesicant]] | ||
| + | [[Category:Alkylating agents]] | ||
| + | |||
[[Category:Orphan drug]] | [[Category:Orphan drug]] | ||
Revision as of 20:28, 19 November 2020
General information
Class/mechanism: Alkylator, binds to the minor groove of DNA, which distorts the DNA helix and its major groove. This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.[1][2][3]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Trabectedin (Yondelis) package insert[1]
- Trabectedin (Yondelis) patient drug information from manufacturer[4]
- Trabectedin (Yondelis) patient drug information (Chemocare)[5]
- Trabectedin (Yondelis) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 10/23/2015: FDA approved for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen.
Also known as
- Code name: ET-743
- Brand name: Yondelis
References
- ↑ 1.0 1.1 1.2 Trabectedin (Yondelis) package insert
- ↑ Trabectedin (Yondelis) package insert (locally hosted backup)
- ↑ Yondelis manufacturer's website
- ↑ Trabectedin (Yondelis) patient drug information from manufacturer
- ↑ Trabectedin (Yondelis) patient drug information (Chemocare)
- ↑ Trabectedin (Yondelis) patient drug information (UpToDate)